Gemini 4 Argon: What’s New, Who Can Use It, and Intro Pricing
Google’s Gemini 4 Argon frontier model: 1M unified context, who gets access (API, Ultra/Pro, Fairwind), and introductory pricing through Nov 30, 2026 — from blog.google and ai.google.dev.
Retatrutide Explained: Triple-Agonist Weight-Loss Drug, Phase 3 Results, and What to Know Before FDA Filing
Retatrutide is Lilly’s investigational GIP/GLP-1/glucagon triple agonist. Phase 3 TRIUMPH results, side effects, black-market warnings, and a planned BLA around Q1 2027 — with sources to verify.
